Department of Clinical Sciences of Companion Animals, Utrecht University, Utrecht, The Netherlands.
Vet Comp Oncol. 2011 Dec;9(4):283-9. doi: 10.1111/j.1476-5829.2011.00266.x. Epub 2011 Apr 18.
Safety and efficacy of pegylated liposome encapsulated doxorubicin (PL-DOX) was compared with free doxorubicin as an adjuvant monotherapy in dogs with splenic haemangiosarcoma after splenectomy in a randomized prospective clinical trial. A total of 17 dogs in each group were treated. No significant difference in survival between the two treatments was found. The calculated median overall survival time for the 34 dogs was 166 days [95% confidence interval (CI) 148-184]. The ½ year and one-year survival was 41.2% (95% CI 24.8-56.9) and 22.7% (95% CI 9.9-37.4), respectively. In dogs treated with PL-DOX, a desquamating dermatitis like palmar-plantar erythrodysesthesia (PPES) was seen in two dogs, while three other dogs showed anaphylactic reactions. Cardiotoxicity was not seen in either treatment groups.
聚乙二醇脂质体阿霉素（PL-DOX）的安全性和疗效在一项随机前瞻性临床试验中与游离阿霉素作为辅助单药进行了比较，用于治疗脾切除术后患有脾血管肉瘤的犬。每组 17 只狗接受治疗。两种治疗方法之间的生存无显著差异。34 只狗的中位总生存时间计算为 166 天[95%置信区间（CI）148-184]。半年和一年的生存率分别为 41.2%（95%CI 24.8-56.9）和 22.7%（95%CI 9.9-37.4）。在接受 PL-DOX 治疗的犬中，有 2 只出现了剥脱性皮炎样掌跖红细胞增多症（PPES），而另外 3 只出现了过敏反应。在任何治疗组中均未观察到心脏毒性。
